Prospera Financial Services Inc Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Prospera Financial Services Inc trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 62,130 shares of the company’s stock after selling 3,027 shares during the quarter. Johnson & Johnson accounts for about 0.5% of Prospera Financial Services Inc’s holdings, making the stock its 21st largest holding. Prospera Financial Services Inc’s holdings in Johnson & Johnson were worth $11,021,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of JNJ. Patron Partners LLC grew its position in Johnson & Johnson by 12.7% during the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after acquiring an additional 747 shares during the last quarter. Tandem Investment Advisors Inc. grew its position in Johnson & Johnson by 4.8% during the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after acquiring an additional 15,003 shares during the last quarter. Argent Advisors Inc. grew its position in Johnson & Johnson by 6.6% during the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock worth $3,504,000 after acquiring an additional 1,218 shares during the last quarter. Exeter Financial LLC grew its position in Johnson & Johnson by 3.2% during the 1st quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock worth $4,684,000 after acquiring an additional 819 shares during the last quarter. Finally, Fusion Capital LLC grew its position in Johnson & Johnson by 7.8% during the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock worth $4,935,000 after acquiring an additional 2,019 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Trading Down 0.4 %

JNJ opened at $171.11 on Friday. The stock has a market cap of $449.88 billion, a PE ratio of 24.91, a PEG ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The business has a 50 day moving average of $175.21 and a 200-day moving average of $174.55. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.48 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Analyst Ratings Changes

Several research firms recently issued reports on JNJ. SVB Leerink reduced their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.